Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis-Reference-Cited by-同舟云学术

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

Published:2021-07-16 Issue:5 Volume:2 Page:434-449
ISSN:2643-3230
Container-title:Blood Cancer Discovery
language:en
Short-container-title:Blood Cancer Discov

Author:

Wang Victoria E.,Blaser Bradley W.,Patel Ravi K.^ORCID,Behbehani Gregory K.,Rao Arjun A.,Durbin-Johnson Blythe,Jiang Tommy^ORCID,Logan Aaron C.^ORCID,Settles Matthew,Mannis Gabriel N.,Olin Rebecca,Damon Lloyd E.^ORCID,Martin Thomas G.,Sayre Peter H.,Gaensler Karin M.,McMahon Emma,Flanders Michael,Weinberg Vivian,Ye Chun J.,Carbone David P.^ORCID,Munster Pamela N.,Fragiadakis Gabriela K.,McCormick Frank^ORCID,Andreadis Charalambos

Funder

NCI

Damon Runyon Postdoctoral Award

ASCO Young Investigator Award

Lung Cancer Research Foundation

Department of Defense

NIDDK

Gateway for Cancer Grant

Publisher

American Association for Cancer Research (AACR)

Subject

General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DrugFormer: Graph‐Enhanced Language Model to Predict Drug Sensitivity;Advanced Science;2024-08-29

2. T Cell-Mediated Tumor Killing Sensitivity Gene Signature-Based Prognostic Score For Acute Myeloid Leukemia;2024-01-25

3. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation;Leukemia;2023-11-02

4. CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis;2023-02-21

5. Phase Ib and Expansion Study of Gemcitabine,Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer;The Oncologist;2023-02-18